The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway by Caroline Wilson et al.
Wilson et al. BMC Cancer  (2015) 15:55 
DOI 10.1186/s12885-015-1066-7RESEARCH ARTICLE Open AccessThe differential anti-tumour effects of zoledronic
acid in breast cancer – evidence for a role of the
activin signaling pathway
Caroline Wilson1*, Penelope Ottewell2, Robert E Coleman1 and Ingunn Holen1Abstract
Background: Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with
oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism
behind this differential anti-tumour effect according to ER status, hypothesising it may in part be mediated via the
activin signaling pathway.
Methods: The effects of activin A, its inhibitor follistatin and zoledronic acid on proliferation of breast cancer cells
was evaluated using either an MTS proliferation assay or trypan blue. Secretion of activin A and follistatin in conditioned
medium (CM) from MDA-MB-231, MDA-MB-436, MCF7 and T47D cell lines were measured using specific ELISAs. The
effects of ZOL on phosphorylation domains of Smad2 (pSmad2c + pSmad2L) were evaluated using immunofluorescence.
Changes seen in vitro were confirmed in a ZOL treated subcutaneous ER-ve MDA-MB-436 xenograft model.
Results: Activin A inhibits proliferation of both ER-ve and oestrogen positive (ER + ve) breast cancer cells, an effect
impaired by follistatin. ZOL significantly inhibits proliferation and the secretion of follistatin from ER-ve cells only,
which increases the biological activity of the canonical activin A pathway by significantly increasing intracellular
pSmad2c and decreasing nuclear accumulation of pSmad2L. In vivo, ZOL significantly decreases follistatin and
pSmad2L expression in ER-ve subcutaneous xenografts compared to saline treated control animals.
Conclusions: This is the first report showing a differential effect of ZOL, according to ER status, on the activin
pathway and its inhibitors in vitro and in vivo. These data suggest a potential molecular mechanism contributing
to the differential anti-tumour effects reported from clinical trials and requires further evaluation in clinical samples.
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The addition of ZOL to neo-adjuvant chemotherapy has
been shown to enhance the response of invasive breast
cancer to chemotherapy [1]. However, not all breast tu-
mours are equally responsive to the drug, with some
studies suggesting that ZOL has a greater effect on pri-
mary tumour response and disease recurrence in patients
with ER-ve, as opposed to ER + ve, tumours [2,3]. In vitro,
ZOL inhibits proliferation and induces apoptosis of the
ER-ve cell line MDA-MB-231, an effect not seen in the
ER + ve cell line MCF7 [4]. The anti-tumour effects of* Correspondence: c.wilson@sheffield.ac.uk
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unless otherwise stated.ZOL reported from in vitro studies include reduced adhe-
sion, migration and invasion of tumour cells, mediated
by inhibition of farnesyl diphosphate (FPP) synthase and
reduced prenylation of small GTPases (enzymes that
hydrolyze guanosine triphosphate) [5].
The clinical neo-adjuvant breast cancer study, ANZAC,
evaluated the biological effects of addition of ZOL to first
cycle of FEC100 chemotherapy, and showed serum levels
of follistatin significantly decreased following administra-
tion of ZOL in postmenopausal women [6]. Furthermore
the addition of ZOL to chemotherapy reduced serum
follistatin levels at day 5 post treatment specifically in
patients with ER-ve tumours compared to patients receiv-
ing chemotherapy alone [7]. This may reflect a fall in theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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not seen in ER + ve tumours.
Follistatin is a paracrine antagonist of activin and both
proteins modify breast cancer cell proliferation. Activin
is produced by breast cancer cells, inhibiting their prolif-
eration, while follistatin binds to activin and prevents re-
ceptor binding with the type II receptor (ActRII), thus
promoting proliferation [8]. Once activin binds to ActRII,
dimerization occurs with ActRIB and the receptor associ-
ated intracellular proteins Smad2 and 3 are phosphory-
lated (Figure 1) [9]. Smad phosphorylation occurs either at
the C terminus or at a linker region joining the MH1 and
MH2 domains, with different effector functions; the C
terminus being a tumour suppressor and the linker region
being a tumour promoter [10] (Figure 1). ER-ve breast
cancer cell lines have been shown to be insensitive to the
anti-proliferative effects of activin [11], however this effect
does not appear to be due to low expression of the activin
type II receptor, with evidence that MDA-MB-231 express
activin type II receptors [11] and MDA-MB-436 have a
functional activin-signaling pathway showing phosphoryl-
ation of Smad2 in response to exogenous activin following
removal of follistatin from the medium [12]. These data
indicate that exogenous neutralisers of activin, i.e. follista-
tin, are responsible for the lack of inhibition of prolifera-
tion in response to activin in ER-ve cell lines, rather than
absence of/non functional activin receptors.Figure 1 The canonical activin pathway. Activin binds to activin type II r
(pSmad2C) or smad3 followed by nuclear translocation with co-receptor Sma
Phosphorylation at the linker region of Smad2 or smad3 occurs downstream
dependent kinases. The effector function of phosphorylated Smad2 is depend
in tumour growth suppression and linker phosphorylation resulting in tumouWe provide the first evidence that ZOL can affect the
activin signaling pathway specifically in ER-ve breast can-
cer cell lines by a dual mechanism; decreasing secretion of
follistatin and preventing nuclear localization of linker
phosphorylated Smad2.
Methods
Cell lines and reagents
ER-ve (MDA-MB-231, MDA-MB-436) and ER + ve (MCF7,
T47D) human breast cancer cells were purchased from
European Collection of Cell Lines and routinely cultured in
RPMI + 10% foetal calf serum (FCS). Evaluation of secretion
of proteins from cell lines into conditioned medium (CM)
and effects on pSmad2C was performed using human acti-
vin A and follistatin quantikine ELISAs and the cell based
phospho-Smad2/3 fluorescent ELISA, purchased from
R&D systems (Oxford, UK). Cell titre 96 Aqueous One
solution cell proliferation assay (MTS) was purchased
from Promega (Southampton, UK). The tumour samples
were obtained from MDA-MB-436 previously described
xenograft studies [13]. Recombinant human activin A and
follistatin were purchased from R&D systems (Oxford,
UK). ZOL ([(1-hydroxy-2-(1H-imidazol-1-yl) ethylidene]
bisphosphonic acid) was supplied as the hydrated di-
sodium salt by Norvartis Pharma (Basel, Switzerland).
Primary antibodies were purchased from Santa Cruz USA
(Rap1a), Abcam UK (GAPDH) and Cell Signaling UKeceptors resulting in phosphorylation of the C terminus of Smad2
d4. Follistatin binds to activin preventing binding the type II receptor.
of cytoplasmic proteins such as RAS and nuclear proteins such as cyclin
ent on the site of phosphorylation; C terminus phosphorylation resulting
r growth promotion.
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was purchased from Tocris bioscience (Bristol, UK).
Western blotting
Cells were lysed in cell lysis buffer (Sigma-Aldrich) and pro-
teins were resolved using 12% SDS-PAGE. Proteins were
immobilized on polyvinylidene difluoride (PVDF) mem-
brane, blocked (5% milk) and probed with antibodies
specific to unprenylated Rap1a (1:200), pSmad2L (1:1000),
with GAPDH (1:20,000). Representative blots from three
separate experiments are shown.
Enzyme linked immunoabsorbance assays
Human Follistatin and Activin A ELISAs were carried
out according to the manufacturers instructions using
CM from tumour cells. Minimum detection limits were
29 pg/ml and 3.67 pg/ml, respectively, with intra-assay
CVs <15%. Molar ratios were calculated as follows; mean
CM concentrations (pmol/L) divided by molecular weight
of the protein, expressed as a ratio (follistatin:activin).
The quantification of total smad2/3 to phosphoSmad2/3
was carried out using a cell based phospho-Smad2/3 fluor-
escent ELISA. 1.5x103 MDA-MB-231 cells were seeded in
a 96 well plate and the ELISA was carried out according
to the manufacturers instructions.
Proliferation assay
Cell proliferation was assessed either using an MTS
assay or viable cell counting with trypan blue. For the
MTS assay 1.5x103 MDA-MB-231/3x103 MCF7 cells were
seeded in 96 well plates and for the trypan blue assay
1x105 cells were seeded in 6 well plates. Cells were serum
starved for 24 hours before addition of recombinant
protein/drug in RPMI + 10%FCS, cells were washed and
protein/drug replaced every 24 hours. At completion of
the MTS assay 20 μl of MTS solution was added directly to
each well and quantified on a plate reader. At completion
of the trypan blue assay cells were trypsinised to remove
from wells and trypan added in a 50:50 concentration of
cell suspension to trypan blue and counted using a
haemocytometer.
Immunofluorescence
To visualize pSmad2C and pSmad2L, 2x104 MDA-MB-
231/4x104 MCF7 cells were seeded in chamber slides,
serum starved for 24 hours and then treated for 48 hours
with ZOL (50 μM). Cells were fixed (4% paraformalde-
hyde) and blocked (5% goat serum) prior to incubation
with phosphoSmad2 antibodies (1:100). After incubation
with secondary antibodies (1:100) and fluorescein-avidin,
coverslips were mounted with DAPI and viewed on an
inverted fluorescent light microscope. Images of ≥100 cells
per chamber manually scored for nuclear localization
using the blue dapi counter stain as a nuclear localiser.Immunohistochemical staining for follistatin and
pSmad2L
Paraffin embedded tumour sections from previously
published in vivo experiments were used [13]. The
in vivo experimental design used female MF1 nude mice
injected with 5x105 MDA-MB-436 cells sub-cutaneous
and animals were treated weekly with 100 μg/kg intra
peritoneal ZOL vs. saline control for 6 weeks starting
on day 7. Tumours were processed for histology using
standard protocols. Sections were dewaxed, blocked
(3% H2O2 in methanol) for 10 minutes followed by
trypsin antigen retrieval for 15 minutes at 37°C. Further
blocking (5% goat serum/1% bovine serum albumin)
for 30 minutes was followed by addition of primary
antibody overnight (pSmad2L 1:100/follistatin 1:200).
Secondary antibodies were added (1:200) for 30 minutes
followed by a 6-minute incubation with DAB. All animal
experiments were carried out in accordance with local
guidelines and with Home Office approval under project
license 40/2343 held by Professor N. J. Brown, University
of Sheffield, UK.
Statistical analysis
Unless stated otherwise, all experiments were carried out
with 3 replicates and 3 repeats. Prism GraphPad (5.0a)
was used for statistical analysis. Data analysis was by non-
parametric Mann–Whitney test to compare differences
between groups or Wilcoxon Signed-Rank test to compare
related groups. Data represent mean and SEM. Statistical
significance is defined as a p value = <0.05.
Results
Activin A inhibits the proliferation of ER + ve and ER-ve
breast cancer cells
Previous reports have shown that proliferation of ER + ve
cells is inhibited by activin [14], but the effect of activin on
proliferation of ER-ve cell lines is less clear [11]. In order
to compare the effect of activin and follistatin on prolifera-
tion in ER-ve and ER + ve cell lines, a time course and
dose response MTS assay was performed. Both the ER-ve
(MDA-MB-231) and ER + ve (MCF7) cells showed a sig-
nificant decrease in proliferation compared to control fol-
lowing addition of activin A on days 1 and 3 (Figure 2A +B)
which was lost by day 5 (data not shown). There was a
significant dose-dependent inhibition of proliferation
with increasing doses of activin A in both cell lines.
These results show that both ER-ve and ER + ve cell lines
are responsive to the growth inhibitory effect of activin A.
To confirm the decrease in proliferation was occurring in
an activin dependent manner in ER-ve cell lines given the
controversy in the literature, MDA-MB-231 cells were
treated with activin 6000 pg/ml +/− an ALK4/5 inhibitor
SB-431-542 (10 μM/l) for 72 hours. The ALK4/5 inhibitor
will prevent ActRII dimerising with its type I receptor
Figure 2 Activin inhibits breast cancer cell proliferation. MDA-MB −231 (A + C) and MCF7 (B + D) cells were treated with increasing doses of
activin in a timecourse experiment (A + B), or with recombinant activin (6000 pg/ml) +/− follistatin (64,000 pg/ml) for 72 hours (C + D). 20 μl of MTS
solution was added 4 hours prior to the final time points to evaluate absorbance of treated cells relative to control untreated cells. Data represents
mean + SEM of 8 replicates and 5 repeats. Wilcoxon Signed-Rank test for significance, *p value <0.05, NS not significant.
Wilson et al. BMC Cancer  (2015) 15:55 Page 4 of 11ALK4. MDA-MB-231 cells showed less inhibition of pro-
liferation with addition of the ALK4/5 inhibitor to activin
(mean % change in absorbance from control Activin; −11%,
Activin +ALK4/5 inhibitor −3.4%) confirming the changes
in proliferation in ER-ve cells was activin-dependent (data
not shown).
Follistatin impairs the inhibition of proliferation induced
by activin A
Follistatin is reported to negate the anti-proliferative
effect of activin [12]. In order to evaluate the effect of
follistatin in ER-ve (MDA-MB-231) and ER + ve (MCF7)
cells they were treated with 6000 pg/ml of activin A in the
presence or absence of follistatin (64,000 pg/ml) for
72 hours (activin concentrations were chosen to repli-
cate inter-tumoural levels of activin in breast tumours
[15]). The significant inhibitory effect of activin A on
cell proliferation was negated in the presence of follistatin
in MDA-MB-231 cells (mean % change from control;
Activin −6% [SEM 0.92], Activin + follistatin +2.6% [SEM1.9]). In MCF7 cells a similar, but non-significant,
trend was also seen (mean % change from control;
Activin −3.2% [SEM 1.3], Activin + follistatin −0.02%
[SEM 2.4]) (Figure 2C + D). These data provided fur-
ther indication that ER-ve cell lines are sensitive to the
growth inhibitory effects of activin A and that this ef-
fect is inhibited by follistatin.
ER-ve cells secrete more activin A and follistatin than ER +
ve cells
The quantity of activin A and follistatin secreted from
ER-ve (MDA-MB-231 and MDA-MB-436), and ER + ve
(MCF7 and T47D) cells was determined by ELISA. As
shown in Figure 3A, both ER-ve cell lines secreted sig-
nificant levels of activin A (MDA-MB-231 = 561 pg/ml
[SEM 104.9] p value = 0.0034, MDA-MB-436 = 430 pg/ml
[SEM 73.8] p value = 0.0436). Follistatin was detectable
in the medium from all cell lines, although the levels
were much lower in ER + ve cell lines (mean level pg/ml;
MCF7 = 200, T47D= 108) compared to ER-ve cell lines
Figure 3 Activin and follistatin secretion from ER- breast cancer cell lines and ER + ve breast cancer cell lines. 1x105 MDA-MB-231 or
MDA-MB-436 (ER-ve) and 4x105 MCF7 or T47D (ER + ve) cell lines were plated in 6 well plates and levels of Activin (A) and follistatin (B) in the
medium determined by ELISA at 24 and 48 hours. Data represents 3 replicates and 3 repeats. Mann Whitney test for significance comparing wells
with cells to media alone (no cells), *p value <0.05. <MDL = below assay minimum detection limit.
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436 = 1704 Figure 3B). These results suggest that ER-ve
cells could be more dependent on activin A for regula-
tion of cell growth than ER + ve cells, and may utilise
secretion of follistatin as a mechanism of escape from
the anti-proliferative effects of activin A. There is no clear
evidence to indicate why tumor cells secrete a growth
inhibitor such as activin [16], suggesting it may be have
alternative functions that the cells escape from by alter-
native mechanisms i.e. secretion of inhibitors or down
regulation of receptors.
Zoledronic acid differentially affects proliferation of
breast cancer cell lines according to ER status
To evaluate if zoledronic acid could affect proliferation
of ER + ve and ER-ve breast cancer cell lines MDA-MB-
231, MDA-MB-436, T47D and MCF7 cells were treated
with 50 μM ZOL or medium control for 48 hours and
live cell count performed with trypan blue. ZOL signifi-
cantly inhibited proliferation of both ER-ve cell lines com-
pared to control (Cell count x105; MDA-MB-231 control
3.4 [SEM 0.79], ZOL 1.6 [SEM 0.25] p value 0.0009,
MDA-MB-436 control 6.9 [SEM 0.33] ZOL 5.3 [SEM
0.14] p value 0.0043), but did not significantly alter pro-
liferation of the ER + ve cell lines MCF7 and T47D
(Figure 4).
Zoledronic acid decreases follistatin secretion from ER-ve
cell lines only
To investigate if ZOL could affect the secretion of acti-
vin A and/or follistatin from MDA-MB-231 and MCF7cells, both cell lines were exposed to medium +/− 25 μM/
50 μM ZOL for 48 hours. Activin A secretion was un-
affected by ZOL in either cell line. In contrast, follistatin se-
cretion was significantly decreased in MDA-MB-231 cells
after exposure to ZOL (control 23378 pg/ml [SEM 5259],
ZOL 9987 pg/ml [SEM 2871], p value =0.0012), and also fell
in MDA-MB-436 cells (control 1928 pg/ml [SEM 188],
ZOL 1592 pg/ml [SEM 65] p value 0.07), but did not change
in MCF7 (Figure 5) or T47D cells (data not shown). We hy-
pothesise that the biological activity of activin A depends on
the ratio of activin A to follistatin in the tumour microenvir-
onment. The literature reports a 4:1 molar ratio of follista-
tin:activin would neutralize activin [17]. ZOL reduced the
molar ratio of follistatin:activin secreted by MDA-MB-231
cells (control ratio 14:1, ZOL ratio 4:1) (Figure 5B), com-
pared to minimal change in MCF7 cells (control ratio 3:1,
ZOL ratio 4:1) (Figure 5D) indicating ZOL has a more no-
ticeable effect on the follistatin:activin ratio in ER-ve cell
lines.
To evaluate the effects of a short (clinically achievable)
exposure of ZOL on follistatin secretion in ER-ve cell
lines, MDA-MB-231 and MDA-MB-436 cells were treated
with 50 μM ZOL for 4 hours, followed by 44 hours incu-
bation in drug-free medium. The secretion of follistatin
was significantly decreased in both cell lines by a 4-hour
pulse of ZOL (mean follistatin pg/ml, MDA-MB-231;
control = 17551 [SEM 847], ZOL = 6106 [SEM 1315]
p value =0.0015. MDA-MB-436; control = 3209 [SEM 236],
ZOL =1667 [SEM 116] p value = 0.001) (Figure 6A). These
data show that even a short exposure to ZOL decreases fol-
listatin secretion from ER-ve cell lines.
Figure 4 Effects of zoledronic acid on proliferation of ER + ve and ER-ve cell lines. 1x105 MDA-MB-231, MDA-MB-436 (ER-ve),MCF7 or T47D
(ER + ve) cell lines were plated in 6 well plates. Cell were treated for 48 hours with medium +/− 50 μM ZOL. At 48 hours viable cell count was
performed using trypan blue. Data represents 3 replicates and 3 repeats. Mann Whitney test for significance comparing control with ZOL treated,
NS not significant, **p value < 0.005, ***p value <0.0005.
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ZOL increases accumulation of unprenylated small GTPases
i.e. Rap1a via inhibition of the mevalonate pathway [18].
The lack of effect of ZOL on follistatin secretion in the
ER + ve cells was considered to possibly reflect a limited
drug uptake. To evaluate if the ER + ve and ER-ve cell
lines used in this study had a similar levels of ZOL up-
take we used western blotting to compare the accumu-
lation of unprenylated Rap1a (uRap1a, a surrogate marker
of ZOL uptake) in MCF7 and MDA-MB-231 cells treated
with ZOL, and if addition of the mevalonate pathway
intermediary, geranylgeraniol (GGOH), could inhibit the
accumulation of uRap1a. Both cell lines had increased
levels of uRap1a in response to treatment with ZOL that
was partially reversed by addition of GGOH (Figure 6B).
These data suggest that the difference in follistatin secre-
tion between ER-ve and ER + ve cell lines is not due differ-
ential cellular uptake of ZOL.
Zoledronic acid reduces intracellular C terminus
phosphorylated Smad2
To evaluate if the activin-signaling pathway downstream
of surface receptors is affected by ZOL, localization and
intracellular quantity of pSmad2C in MDA-MB-231 and
MCF7 cells was assessed. Using an immunofluorescence
method, we detected no significant difference in the per-
centage of cells with nuclear localization of pSmad2C
after treatment with ZOL compared to control in eithercell line (Figure 7A-C). However, MDA-MB-231 cells
exposed to CM from ZOL treated cells (containing low
levels of follistatin) showed significantly higher levels of
pSmad2C than cells exposed to CM from medium only
treated cells (control = 0.29 [SEM 0.065], ZOL = 0.7
[SEM 0.14], p value 0.0286) (Figure 7D). This effect was
not seen in MDA-MB-231 cells exposed directly to
50 μM ZOL, indicating that the decreased follistatin
levels in CM from ZOL treated cells was responsible
for the increase in intracellular levels of pSmad2C.
Zoledronic acid decreases nuclear localization of linker
phosphorylated Smad2
Whereas pSmad2C is recognized to function as a tumour
suppressor in breast cancer [19], pSmad2L may act as a
tumour growth promoter [10]. We evaluated if ZOL could
affect cellular localization of pSmad2L in MDA-MB-231
and MCF7 cells using immunofluorescence. The percent-
age of MDA-MB-231 cells with nuclear localization of
pSmad2L was significantly decreased after treatment with
ZOL (control = 50% [SEM 4.6], ZOL =6.6% [SEM 1.1],
p value <0.0001). No significant difference was seen be-
tween ZOL and control in the MCF7 cells (Figure 7E-G).
Using western blotting we found that ZOL did not
cause a significant alteration in the total cellular levels
of pSmad2L, suggesting that ZOL alters cellular localization
of pSmad2L in MDA-MB-231, but not the total quantity
(Figure 7H).
Figure 5 Effects of zoledronic acid on follistatin secretion and follistatin:activin ratio. MDA-MB-231 (A) and MCF7 (C) cells were treated
with medium alone, 25 μM or 50 μM ZOL for 48 hours and levels of secreted activin and follistatin measured by ELISA. Molar ratio of follistatin:
activin (B + D) was calculated by converting mean quantity of secreted protein per million cells (pg/ml) to pmol/l by dividing by the molecular
weight of each protein, and then expressed as a ratio. A molar ratio of 4 (dashed line) represents the level at which activin is neutralised by follistatin:
an excess of follistatin:activin increases tumour growth (above dashed line). Data represents mean + SEM of 3 replicates and 3 repeats,
*= p value <0.05, NS not significant.
Figure 6 Effects of pulsed zoledronic acid on follistatin secretion from ER-ve cell lines. The difference in follistatin secretion according
to ER status is not due to differences in cellular uptake of the drug. A. MDA-MB-231 and MDA-MB-436 cells were treated for 4 hours with
50 μM of ZOL followed by a 44 hour incubation with medium alone or medium alone for 48 hours (CON). Follistatin levels in the supernatant
was removed and processed for ELISA. Data represents mean + SEM of 3 replicates and 3 repeats, **= p value <0.01, ***= p value <0.001. B. MDA-
MB-231 and MCF7 cells were treated for 48 hours with medium alone (C), GGOH 50 μM (G), Zol 10 μM (Z) or both G and Z in combination (ZG).
Rap1a antibody (1:200) used to assess levels of unprelylated protein and GAPDH (1:20,000) used as loading control.
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Figure 7 Smad2 phosphorylation at both c terminus and linker region is differentially affected by zoledronic acid according to ER
status of breast cancer cells. A + B Representative immunofluorescent images of pSmad2C (green) and dapi staining (blue) in MDA-MB-231 cells
(A) and MCF7 cells (B) treated with medium alone (C) or ZOL (Z) for 48 hours. C. Quantification of nuclear localisation of pSmad2C in MDA-MB-
231 and MCF7 cells treated for 48 hours with medium alone (con) or ZOL (50 μM). Data represents minimum 100 cells per group, Mann Whitney
U test for significance, NS = not significant D. Ratio of total cellular quantity of total Smad2/3 to pSmad2/3 in MDA-MB-231 cells treated for 1 hour
with medium alone, ZOL (50 μM) or conditioned medium (CM) from MDA-MB-231 cells previously treated with ZOL (50 μM) or medium
(control). Data represents 3 replicates and 3 repeats, Mann Whitney U test for significance, NS = not significant, *p = <0.05 E + F Representative
immunofluorescent images of pSmad2L (green) and dapi staining (blue) in MDA-MB-231 cells (E) and MCF7 cells (F) treated with medium alone (C) or
ZOL (Z) for 48 hours. G. Quantification of nuclear localisation of pSmad2L in MDA-MB-231 and MCF7 cells treated for 48 hours with medium
alone (con) or ZOL (50 μM). Data represents minimum 100 cells per group, Mann Whitney U test for significance, NS = not significant, ***p value <0.001.
H. Representative western blots for cellular quantity of pSmad2L and gapdh in MDA-MB-231 cells treated with medium alone (con) or ZOL (50 μm).
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expression in an ER-ve xenograft model
In order to validate that ZOL induces changes in follistatin
and pSmad2L in ER-ve tumours in vivo, ER-ve MDA-MB-
436 sub-cutaneous tumour sections from mice treated
with or without ZOL (100 μg/kg, weekly for 6 weeks,
equivalent to the 4 mg clinical dose) were evaluated.
Follistatin expression was scored for intensity and area
of positive stain. Data were analysed using average scores
from 2 assessors blinded to the treatment groups. No dif-
ference was seen in the intensity of follistatin staining,
however, there was a significant decrease in the tumour
area staining positive for follistatin in mice treated with
ZOL compared to saline (Figure 8A-D). The number of
cells with mitotic nuclei staining positive for pSmad2L
was significantly lower in tumours from ZOL treated mice
compared to saline treated (Figure 8E-F). These resultssuggest that using the dosing regime described, ZOL can
directly alter expression of both follistatin and pSmad2L
in ER-ve subcutaneous tumours in vivo.
Discussion
In this study we describe a novel anti-proliferative mech-
anism of action of ZOL in ER-ve breast cancer cells, in-
volving the activin-signaling pathway, and suggest that
this may contribute to the enhanced anti-tumour effect
of ZOL in ER-ve breast cancers demonstrated in neo-
adjuvant clinical trials [2,20].
In agreement with published data, we found that acti-
vin A inhibits proliferation of ER + ve MCF7 cells [21].
However, we saw a very similar inhibition of growth in
ER-ve MDA-MB-231 cells, in contrast to previously re-
ported data [10]. Kalkoven et al. suggested the mechanism
responsible for resistance to the anti-proliferative effects
Figure 8 Follistatin and pSmad2L expression in MDA-MB-436 xenografts is reduced following zoledronic acid treatment in vivo.
A. Representative images of follistatin expression in tumours from saline treated mice at x1.6 magnification (left) and x20 magnification (right).
Viable tumour cells (T), necrotic core of tumours (NC). B Representative images of follistatin expression in tumours from ZOL treated mice. C + D.
20 x 750 μm2 images were scored from two sections per tumour. Images were scored for intensity of + ve stain (C) and area of + ve stain (D).
Data represents the mean scores + SEM. Mann Whitney U test for significance, ***p value <0.001, NS not significant. E Representative images of
pSmad2L expression (black arrows) in saline treated mice (C) and ZOL treated mice (Z). F 20x750μm2 images were scored from two sections
per tumour. Number of positive cells were counted and data represents mean scores + SEM. Mann Whitney U test for significance, ***p value <0.001.
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however, alternative mechanisms such as the presence
and/or effect of secreted activin neutralizers like follistatin
was not evaluated.
Breast cancer cells have been shown to express the
follistatin related gene (FLRG), encoding follistatin and
follistatin related protein [12]. This same study also
demonstrated that the anti-proliferative effect of activin
was weak in MCF7 and undetectable in MDA-MB-436
cells. However, when endogenous secreted inhibitors i.e.
follistatin were removed, Smad2C was phosphorylated in
response to activin in both cell lines, and silencing of
FLRG increased levels of pSmad2C and decreased pro-
liferation in response to endogenous activin. These results
support our data, demonstrating that activin inhibitorssuch as follistatin can neutralise the anti-proliferative
effects of activin in both ER-ve and ER + ve cell lines.
We found that both activin A and follistatin were se-
creted from ER-ve and ER + ve cells, but at different levels,
hence generating different effects on tumour cell prolifera-
tion. ER-ve cells secreted an excess of follistatin:activin,
favouring cell proliferation, and in contrast to ER + ve cells
which secreted an excess of activin:follistatin, favouring
growth suppression. Previously published data have dem-
onstrated that the activin βA subunit is detected in higher
levels in breast carcinoma compared to normal breast
tissue [15], and activin type II cell surface receptors were
attenuated with increasing tumour grade [22]. These stud-
ies did not include measurements of follistatin expression.
It is possible that resistance to the tumour suppressive
Wilson et al. BMC Cancer  (2015) 15:55 Page 10 of 11actions of activin in breast cancer is linked to the levels of
secretion of activin neutralizing molecules such as follista-
tin, as well as a concurrent decrease in expression of acti-
vin type II receptors. This potential mechanism requires
exploration in clinical neo-adjuvant breast cancer studies.
The differential effect of ZOL on follistatin secretion
according to ER status of breast cancer cell lines in vitro
and in vivo demonstrated in this study, has not been
previously reported. However, other studies have shown
a differential effect of ZOL on proliferation according to
ER status. Rachner et al. demonstrated that MCF7 cells
did not alter proliferation rates in response to ZOL,
whereas MDA-MB-231 cells showed a significant dose-
dependent inhibition of proliferation and increase in apop-
tosis via activation of caspase 3 and 7 [4]. We detected
uRap1a in both MCF7 and MDA-MB-231 cells after treat-
ment with ZOL, suggesting that variable uptake of the
drug is not an explanation for the differing effects on fol-
listatin. This is in agreement with a report by Monkkonen
et al., showing accumulation of uRap1A and isopentenyl
diphosphate (IPP) in both MCF7 and MDA-MB-436 cells
following 24 h treatment with 25 μM ZOL [23]. However,
uptake of 14C-labelled ZOL is reported to be 3 fold lower
in ER-ve BO2 cells compared to ER + ve T47D and MCF-
7 cells one hour after addition of 25 μM ZOL [24]. These
contrasting results may be due to the differences in dose
and time of exposure to the drug. Whether the ZOL-
induced reduction in follistatin secretion from ER-ve cells
is due to a direct effect of the drug on the mevalonate
pathway remains to be established.
We found that the decrease in follistatin secretion from
MDA-MB-231 cells affected the downstream protein
Smad2, increasing the levels of pSmad2/3C relative to
total Smad2/3. Phosphorylation of Smad2 at the C
terminus domain has been shown to suppress breast can-
cer cell invasion and metastases to bone in vivo. In a
mouse model of bone metastasis, Smad2 knockdown in
MDA-MB-231 cells resulted in significantly faster tumour
establishment in bone compared to the parental cell line,
suggesting a tumour suppressive role [25]. In clinical stud-
ies, a tissue microarray study of breast tumours from 426
patients showed that loss of pSmad2C was associated with
a shorter median overall survival (110.5 vs. 306.5 weeks,
p = 0.024), suggesting that this may be a tumour specific
poor prognostic factor [19]. Moreover, phosphorylation of
Smad2 at the linker region has been reported to alter its
action from tumour suppression to tumour promotion.
Phosphorylation at this site is primarily via cytoplasmic
RAS and nuclear cyclin dependent kinases [10], as op-
posed to the canonical receptor-mediated activin path-
way leading to C terminus phosphorylation. Small GTPases
have been found to affect the activin signaling path-
way, with Rap2 increasing activin cell surface receptor
expression, potentially increasing cellular responses toendogenous and exogenous activin [26]. However, RAC1
has been shown to inhibit smad2/3 activation [27], sug-
gesting small GTPases can have differential effects on
the activin pathway. We showed that ZOL decreased
nuclear localization of pSmad2L in ER-ve breast cancer
cells in vitro and the number of cells staining positive
in vivo. Whether this effect of ZOL is via a small GTPase/
RAS dependent mechanism remains to be confirmed, but
ZOL has been shown to decrease RAS expression and ac-
tivity in ER-ve cell lines (MDA-MB-231 and BRC-230),
with inhibition of cell proliferation [28].
Conclusion
Taken together, our data support a potential dual mech-
anism of action of ZOL on the activin signaling pathway
in ER-ve breast cancer cells in vitro and in vivo; firstly
via a decrease in follistatin secretion leading to an in-
crease in the tumour suppressor pSmad2C, and secondly
via a decrease in nuclear localization of the tumour pro-
motor pSmad2L. These data provide a possible novel direct
anti-proliferative mechanism of action of ZOL on breast
cancer cells involving activin signaling, that could contrib-
ute to the enhanced anti-tumour effects of the drug in
neo-adjuvant clinical trials of patients with ER–ve breast
cancer, and requires further research in clinical samples.
The potential indirect anti-proliferative mechanism of ac-
tion of ZOL on breast cancer cells in the bone microenvir-
onment involving activin signaling also requires further
investigation, and may contribute preclinical data to ex-
plain the results of clinical adjuvant bisphosphonate trials
where the burden of residual disease is likely to be within
niches such as the bone.
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